Article
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Proceedings of the National Academy of Sciences of the United States of America - 22 Nov 2016
Okimoto Ross A, Lin Luping, Olivas Victor, Chan Elton, Markegard Evan, Rymar Andrey, Neel Dana, Chen Xiao, Hemmati Golzar, Bollag Gideon, Bivona Trever G
Abstract excerpt
Oncogenic activation of protein kinase BRAF drives tumor growth by promoting mitogen-activated protein kinase (MAPK) pathway signaling. Because oncogenic mutations in BRAF occur in ∼2-7% of lung adenocarcinoma (LA), BRAF-mutant LA is the most frequent cause of BRAF-mutant cancer mortality worldwide. Whereas most tumor types harbor predominantly the BRAFV600E-mutant allele, the spectrum of BRAF mutations in LA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.